2022 American Transplant Congress
Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients
*Purpose: Donor specific antibodies (DSAs) occur in 15-30% of kidney transplant recipients (KTRs) and are associated with rejection and graft loss. Rituximab (RTX), an antiCD20…2022 American Transplant Congress
Reduced CD45RA-CCR7- Tregs Subtypes in Highly Sensitised Patients Associates with a Failure to Regulate Memory IFNγ Production in Response to Donor Alloantigens
*Purpose: Highly sensitised (HS) patients exhibit worse long-term outcomes after kidney transplantation compared to non-sensitised patients. It has been hypothesised that regulatory T cells (Tregs)…2022 American Transplant Congress
NK Cells in Kidney Allograft Antibody-mediated Rejection Display Increased Proliferation, IL-21 Responsiveness, Type-1 Activation, and Cytotoxic Profile
*Purpose: The role of NK cell during antibody-mediated rejection (ABMR) has been previously recognized, but an in-depth characterization of pathways that contribute to such immune…2022 American Transplant Congress
A Signature of Tolerance Which Identifies Subclinical Rejection-Free Patients at One Year After Kidney Transplantation
*Purpose: Spontaneous and rare cases of patients undergoing a functional renal transplant in the absence of immunosuppression represent a particular situation of immune tolerance. We…2022 American Transplant Congress
Social Determinants of Health Are Associated with Pre-Emptive Wait Listing and Do Not Fully Account for Racial Gap in Early Access to the Waitlist
*Purpose: We leveraged a novel data linkage of candidate-level indicators of social determinants of health (SDOH) among kidney waitlist candidates in the United States to…2022 American Transplant Congress
Expanded Experience with Ultra-Short Duration Pangenotypic Direct Acting Anti-Viral (DAA) Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic (HCV) Donors to Hepatitis C Negative Kidney Transplant Recipients (KT)
Virginia Commonwealth University, Richmond, VA
*Purpose: Previous studies have shown that HCV D+/R- kidney transplantation is feasible using 8-12 weeks of DAAs. Utilization of abbreviated regimens may obviate the need…2022 American Transplant Congress
Histologic Borderline Reflects Molecular Injury Not Rejection: Results from the Trifecta Study
*Purpose: In the Trifecta study (NCT04239703), we recently compared indication biopsy diagnoses (MMDx and histology) and plasma %dd-cfDNA levels for indication biopsies (JASN in press…2022 American Transplant Congress
Implementation of Infectious Disease Surveillance in Recently Deceased Human Xenograft Study
NYU Langone Transplant Institute, New York, NY
*Purpose: Xenotransplantation is a promising solution for the ongoing organ shortage but has been slow to develop because of both immunological challenges and potential risk…2022 American Transplant Congress
Medical Necessity Kidney Donation in the Treatment Algorithm for Nutcracker Syndrome: Transforming Pain to Altruism
Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT
*Purpose: Patients with nutcracker syndrome (NCS) are often presented with multiple treatment pathways, including interventional and surgical options. In those who elect native nephrectomy, consideration…2022 American Transplant Congress
Early Outcomes of Single Dose Eculizumab for Abo-Incompatible Living Donor Renal Transplantation
*Purpose: Use of ABO-incompatible (ABOi) donors increases access to living donor renal transplantation (LDRT). Conventional desensitization with plasmapheresis (PLEX) allows safe ABOi transplantation when pre-transplant…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 531
- Next Page »